Novo Nordisk

WorldBrand briefing

AI supplement

Original synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.

Novo Nordisk A/S is a leading Danish multinational pharmaceutical corporation focused on chronic disease care, including diabetes, obesity, cardiovascular conditions, and rare disorders like hemophilia. Founded in 1989 via the merger of two pioneering Danish insulin manufacturers, the company is headquartered in Bagsvaerd, Denmark, and operates in more than 80 countries worldwide.

Key moments

1921University of Toronto researchers discover insulin, spurring Danish efforts to mass-produce the diabetes treatment
1923Two predecessor firms, Novo Terapeutisk Laboratorium and Nordisk Insulaboratorium, are established in Denmark
1985Launches the first NovoPen insulin injection pen, revolutionizing at-home diabetes treatment delivery
1989Merger of the two predecessor companies forms Novo Nordisk A/S
2017Introduces semaglutide (brand name Ozempic) for type 2 diabetes, followed by the oral formulation Rybelsus in 2019
2021FDA approves semaglutide (Wegovy) for chronic weight management in adults with obesity or overweight
2023Becomes Europe's most valuable publicly traded company with a market capitalization over $400 billion

Novo Nordisk is a dominant player in the global diabetes and obesity pharmaceutical markets, with its GLP-1 agonist products reshaping the industry in recent years. The company's competitive position is built on strong intellectual property, extensive global distribution, and a robust research pipeline, though it faces growing challenges from rivals and regulatory pressures.

Holds a leading share of the global insulin and GLP-1 agonist markets, with semaglutide-based products becoming some of the highest-selling drugs worldwide
Key competitors include Eli Lilly (with tirzepatide products Mounjaro and Zepbound) and Sanofi, which offer competing diabetes and obesity treatment lines
Benefits from patent protection for its core semaglutide products through the early 2030s, though generic competitors are emerging in key regional markets like China
Maintains a strong footprint in North America and Europe, with expanding presence in emerging markets across Asia and Latin America
Faces government pricing scrutiny in major markets, as well as supply chain constraints due to surging demand for its obesity treatments

Novo Nordisk has established itself as one of the most trusted and influential brands in the global pharmaceutical industry, with a singular focus on chronic disease care that has built deep loyalty among patients, clinicians, and healthcare systems worldwide. The brand’s association with breakthrough diabetes treatments and more recently, game-changing GLP-1 agonist therapies for obesity, has catapulted its visibility and relevance beyond core medical circles into mainstream public consciousness, cementing its status as an innovation leader in the sector.

The brand benefits from a strong reputation for ethical practice and patient-centricity, rooted in its Danish origins and long history of addressing unmet medical needs. Its sustained investment in research and development, with a pipeline focused on expanding access to chronic disease treatments, supports ongoing brand relevance and differentiation from competitors, even as rivalry in the GLP-1 and diabetes space intensifies.

While regulatory challenges and generic competition on older products create some headwinds, Novo Nordisk’s brand equity remains robust, supported by widespread global distribution and long-standing partnerships with healthcare stakeholders. The brand’s ability to adapt to shifting market demands, including the growing global burden of obesity and diabetes, positions it well to maintain its strength in coming years.

Brand leadership

Score: 90/100

Novo Nordisk holds a clear leading position in the global diabetes care market and dominates the fast-growing GLP-1 agonist segment for obesity treatment, outpacing most competitors in product adoption and clinical credibility. Its brand is widely recognized by clinicians as a gold standard for chronic disease therapies, giving it significant influence over industry trends and global treatment guidelines.

Customer interaction

Score: 82/100

The brand maintains frequent, trusted interactions with both healthcare providers and patient communities, supporting education and access programs for people living with diabetes and obesity. It leverages digital channels and patient advocacy initiatives to build direct connections, though broader public interaction was historically limited compared to consumer-facing brands, even after the rise of its high-demand obesity products.

Brand momentum

Score: 92/100

Driven by the widespread success and popular demand for its GLP-1 products, Novo Nordisk’s brand has seen explosive growth in global awareness and market value in recent years. Its robust pipeline of next-generation chronic disease treatments keeps investor and consumer confidence high, creating strong positive momentum that outpaces most other pharmaceutical brands focused on chronic care.

Brand stability

Score: 88/100

As a well-established multinational with decades of consistent performance in the pharmaceutical sector, Novo Nordisk benefits from strong financial stability and consistent, purpose-aligned brand messaging. It has weathered past patent expirations and regulatory changes without significant erosion of its core brand equity, supported by a diversified product portfolio and loyal stakeholder base.

Brand heritage

Score: 85/100

While the modern Novo Nordisk corporation was formed via merger in 1989, its predecessor companies were pioneering Danish insulin manufacturers dating back to the 1920s, giving it nearly a century of heritage in diabetes care. This long history of innovation and patient care builds deep perceived trust, with the brand’s legacy acting as a major asset rather than a sign of stagnation.

Industry profile

Score: 91/100

Novo Nordisk is one of the most high-profile companies in the global pharmaceutical industry, particularly in the fast-growing chronic disease and weight management segments. Its GLP-1 products have reshaped global industry strategy and drawn significant public and investor attention to the category, making it a benchmark for success in specialty pharmaceutical innovation.

Global brand reach

Score: 83/100

Novo Nordisk operates in more than 80 countries worldwide, with a strong presence in both developed and emerging markets, and a majority of its revenue comes from outside its home region of Europe. While its brand recognition is highest in North America and Europe, it continues to expand access to its products in low- and middle-income markets, steadily increasing its global footprint over time.

AI can support structured reasoning about a brand's underlying value based on public industry data and market position, but any generated estimates are illustrative only and not audited. For a fully verified, audited brand value assessment for Novo Nordisk, contact the World Brand Lab.

Overview

Novo Nordisk A/S

type	Public
traded as	omx: CSE1158 NOVO B OMX Copenhagen 25 component nyse: NVO
key people	Lars Rebien Sørensen (chairman) Maziar Mike Doustdar (president and CEO)
industry	Pharmaceuticals, Health care
products	Activella · Fiasp · Levemir · Norditropin · NovoEight · NovoRapid · NovoSeven · Ozempic · Ryzodeg · Saxenda · Tresiba · Victoza · Wegovy · Xultophy
revenue	dkk309.1 billion (2025)
operating income

net income	dkk102.4 billion (2025)

assets	dkk542.9 billion (2025)

equity	dkk194.0 billion (2025)

num employees	68,794 (2025)

homepage	novonordisk.com

foundation	December 21, 1923

hq location city	Bagsværd

hq location country	Denmark

owner	Novo Holdings A/S (28%)

footnotes	‡R1R‡‡R2R‡

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd.[3] Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.[4]

Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.[5]

Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries.[6] The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[7]

The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017.[8][9][10] In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth.[11] It is a leader in the FTSE4Good Index, and the only European company in the top ten.[12] Novo Nordisk is the largest pharmaceutical company in Denmark.[13] Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe.[14]

History

1922-1925

In 1922, August Krogh, a professor at the University of Copenhagen, went on a lecture tour to North America after receiving the Nobel Prize in Physiology or Medicine. During this tour, Krogh and his wife Marie visited Toronto where the scientists Frederick Banting, Charles Best and John Macleod had just succeeded in manufacturing active insulin. Krogh received permission to manufacture insulin in the Nordic countries and joined forces with Hans Christian Hagedorn, a physician specialising in diabetes, to start the production of insulin in Denmark. This led to the establishment of Nordisk Insulinlaboratorium company in 1923.[15]

In 1925, brothers Harald and Thorvald Pedersen, who were former employees of Nordisk, formed their own company, Novo Terapeutisk Laboratorium. Novo and Nordisk competed until they merged in 1989 to become Novo Nordisk A/S.[16]

1982–1994

Products

Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy.[58] Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.[1]

Toxicogenomics

Novo Nordisk is involved in government funded collaborative research projects with other industrial and governmental partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[59][60] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission.[61]

Research and pipeline

In 2025, Novo Nordisk tested whether semaglutide helped slow progression for Alzheimer’s disease. However, on Nov. 24, 2025, the company announced that the studies failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or with dementia.[62]

Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies.[63] In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.[64]

In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on “transformational biological and technological innovation”.[65]

Controversies

In 2010, Novo Nordisk breached the code of conduct for Association of the British Pharmaceutical Industry (ABPI), by failing to provide information about side-effects of Victoza and by promoting Victoza prior to being granted market authorisation.[66]

In 2013, Novo Nordisk had to pay back dkk3.6billion to the Danish tax authorities due to transfer mispricing.[67]

In March 2013, a debate emerged in which scientists questioned whether the incretin class of diabetic medications – the class to which Victoza belongs – had an increased risk of side effects in the pancreas such as pancreatitis and pancreatic cancer. It was concluded that data currently available did not confirm these concerns.[68]

In October 2013, batches of NovoMix 30 FlexPen and Penfill insulin were recalled in some European countries as their analysis had shown that a small percentage of the products in these batches did not meet the specifications for insulin strength.[69]

Corporate affairs

Finances

For the fiscal year 2024, Novo Nordisk reported earnings of DKK 101 billion (around 14.5 billion USD), with an annual revenue of DKK 290.4 billion (around 42.1 billion USD), an increase of 25% over the previous fiscal cycle.[84][85]

Ownership

Novo Nordisk shares are mostly owned by institutional investors and Novo Holdings A/S. The largest shareholders in 2025 were:[86]

Novo Holdings A/S (28.1%)

External links

References

Annual Report 2024 Novo Nordisk, retrieved February 5, 2025^
Financial report for the period 1 January 2025 to 31 December 2025 Novo Nordisk, February 3, 2026^
Who we are www.novonordisk.com, retrieved 2021-09-28